Trends in Discard of Kidneys from Hepatitis C Viremic Donors in the United States.
Adolescent
Adult
Allografts
/ physiopathology
Antibodies, Viral
/ blood
Antiviral Agents
/ therapeutic use
DNA, Viral
/ blood
Donor Selection
/ statistics & numerical data
Female
Graft Survival
Hepacivirus
/ immunology
Hepatitis C, Chronic
/ drug therapy
Humans
Kidney
/ physiopathology
Kidney Failure, Chronic
/ surgery
Male
Middle Aged
Retrospective Studies
Tissue and Organ Procurement
/ statistics & numerical data
Viral Load
Viremia
/ virology
Young Adult
Hepatitis C virus
deceased donor
kidney discard
nucleic acid amplification testing
Journal
Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570
Informations de publication
Date de publication:
08 02 2021
08 02 2021
Historique:
received:
06
07
2020
accepted:
17
11
2020
pubmed:
17
1
2021
medline:
15
12
2021
entrez:
16
1
2021
Statut:
ppublish
Résumé
Kidneys from hepatitis C virus (HCV) viremic donors have become more commonly accepted for transplant, especially after effective direct-acting antiviral therapy became available in 2014. We examined the contemporary trend of kidney discard from donors with HCV seropositivity and viremia. Data from the Organ Procurement and Transplantation Network were used to identify deceased donor kidneys recovered for transplant. The exposure was donor HCV antibody status in the first analyses, and donor HCV antibody and viremia status in the second analyses. Multilevel, multivariable logistic regression was used to assess the association of these HCV exposure measures with kidney discard, adjusted for donor characteristics. Multilevel analyses were conducted to account for similar kidney discard pattern within clusters of organ procurement organizations and regions. Among 225,479 kidneys recovered from 2005 to 2019, 5% were from HCV seropositive donors. Compared with HCV seronegative kidneys, the odds of HCV seropositive kidney discard gradually declined, from a multivariable-adjusted odds ratio (aOR) of 7.06 (95% confidence interval [95% CI], 5.65 to 8.81) in 2014, to 1.20 (95% CI, 1.02 to 1.42) in 2019. Among 82,090 kidneys with nucleic acid amplification test results in 2015-2019, 4% were from HCV viremic donors and 2% were from aviremic seropositive donors. Compared with HCV aviremic seronegative kidneys, the odds of HCV viremic kidney discard decreased from an aOR of 4.89 (95% CI, 4.03 to 5.92) in 2018, to 1.48 (95% CI, 1.22 to 1.81) in 2019. By 2018 and 2019, aviremic seropositive status was not associated with higher odds of discard (2018: aOR, 1.13; 95% CI, 0.88 to 1.45; and 2019: aOR, 0.97; 95% CI, 0.76 to 1.23). Despite the decrease in kidney discard in recent years, kidneys from viremic (compared with aviremic seronegative) donors still had 48% higher odds of discard in 2019. The potential of these discarded organs to provide successful transplantation should be explored.
Sections du résumé
BACKGROUND AND OBJECTIVES
Kidneys from hepatitis C virus (HCV) viremic donors have become more commonly accepted for transplant, especially after effective direct-acting antiviral therapy became available in 2014. We examined the contemporary trend of kidney discard from donors with HCV seropositivity and viremia.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS
Data from the Organ Procurement and Transplantation Network were used to identify deceased donor kidneys recovered for transplant. The exposure was donor HCV antibody status in the first analyses, and donor HCV antibody and viremia status in the second analyses. Multilevel, multivariable logistic regression was used to assess the association of these HCV exposure measures with kidney discard, adjusted for donor characteristics. Multilevel analyses were conducted to account for similar kidney discard pattern within clusters of organ procurement organizations and regions.
RESULTS
Among 225,479 kidneys recovered from 2005 to 2019, 5% were from HCV seropositive donors. Compared with HCV seronegative kidneys, the odds of HCV seropositive kidney discard gradually declined, from a multivariable-adjusted odds ratio (aOR) of 7.06 (95% confidence interval [95% CI], 5.65 to 8.81) in 2014, to 1.20 (95% CI, 1.02 to 1.42) in 2019. Among 82,090 kidneys with nucleic acid amplification test results in 2015-2019, 4% were from HCV viremic donors and 2% were from aviremic seropositive donors. Compared with HCV aviremic seronegative kidneys, the odds of HCV viremic kidney discard decreased from an aOR of 4.89 (95% CI, 4.03 to 5.92) in 2018, to 1.48 (95% CI, 1.22 to 1.81) in 2019. By 2018 and 2019, aviremic seropositive status was not associated with higher odds of discard (2018: aOR, 1.13; 95% CI, 0.88 to 1.45; and 2019: aOR, 0.97; 95% CI, 0.76 to 1.23).
CONCLUSIONS
Despite the decrease in kidney discard in recent years, kidneys from viremic (compared with aviremic seronegative) donors still had 48% higher odds of discard in 2019. The potential of these discarded organs to provide successful transplantation should be explored.
Identifiants
pubmed: 33451990
pii: 01277230-202102000-00013
doi: 10.2215/CJN.10960720
pmc: PMC7863640
doi:
Substances chimiques
Antibodies, Viral
0
Antiviral Agents
0
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
251-261Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 by the American Society of Nephrology.
Références
Axelrod DA, Schnitzler MA, Xiao H, Irish W, Tuttle-Newhall E, Chang SH, Kasiske BL, Alhamad T, Lentine KL: An economic assessment of contemporary kidney transplant practice. Am J Transplant 18: 1168–1176, 2018 29451350
Voelker R: Cost of transplant vs dialysis. JAMA 281: 2277, 1999
Wong G, Howard K, Chapman JR, Chadban S, Cross N, Tong A, Webster AC, Craig JC: Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities. PLoS One 7: e29591, 2012 22279541
Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Robinson A, Wainright JL, Haynes CR, Snyder JJ, Kasiske BL, Israni AK: OPTN/SRTR 2016 annual data report: Kidney. Am J Transplant 18[Suppl 1]: 18–113, 2018 29292608
McDonnell WM, Lucey MR: Hepatitis C virus transmission during organ transplantation. Hepatology 17: 162–164, 1993 7678573
Pereira BJ, Milford EL, Kirkman RL, Levey AS: Transmission of hepatitis C virus by organ transplantation. N Engl J Med 325: 454–460, 1991 1649402
Roth D, Fernandez JA, Babischkin S, De Mattos A, Buck BE, Quan S, Olson L, Burke GW, Nery JR, Esquenazi V, et al.: Transmission of hepatitis C virus with solid organ transplantation: Incidence and clinical significance. Transplant Proc 25: 1476–1477, 1993 7680166
Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS: Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review. Ann Intern Med 166: 637–648, 2017 28319996
Ladino M, Pedraza F, Roth D: Hepatitis C virus infection in chronic kidney disease. J Am Soc Nephrol 27: 2238–2246, 2016 27095799
Roth D, Ladino M: Transplantation of kidneys from HCV-positive donors: How to best use a scarce resource. J Am Soc Nephrol 28: 3139–3141, 2017 28874402
Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M, Goral S, Forde KA, Bloom RD: Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant 16: 1588–1595, 2016 26604182
Bhamidimarri KR, Ladino M, Pedraza F, Guerra G, Mattiazzi A, Chen L, Ciancio G, Kupin W, Martin P, Burke G, Roth D: Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: A single-center retrospective study. Transpl Int 30: 865–873, 2017 28332729
Alhamad T, Kunjal R, Wellen J, Brennan DC, Wiseman A, Ruano K, Hicks V, Wang M, Schnitzler MA, Chang S-H, Lentine KL: Three‐month pancreas graft function significantly influences survival following simultaneous pancreas‐kidney transplantation in type 2 diabetes patients. Am J Transplant 20: 788–796, 2020 31553823
Chang S-H, Wang M, Liu X, Alhamad T, Lentine KL, Schnitzler MA, Colditz GA, Park Y, Chapman WC: Racial/ethnic disparities in access and outcomes of simultaneous liver-kidney transplant among liver transplant candidates with renal dysfunction in the United States. Transplantation 103: 1663–1674, 2019 30720678
Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, Friedman J, Goldberg D, Hall S, Ison M, Kaiser T, Klassen D, Klintmalm G, Kobashigawa J, Liapakis A, O’Conner K, Reese P, Stewart D, Terrault N, Theodoropoulos N, Trotter J, Verna E, Volk M: The American Society of Transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant 17: 2790–2802, 2017 28556422
Zhu M: Analyzing Multilevel Models with the GLIMMIX Procedure, 2014. Available at: https://support.sas.com/resources/papers/proceedings14/SAS026-2014.pdf . Accessed August 1, 2020
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate [published correction appears in Ann Intern Med 155: 408, 2011]. Ann Intern Med 150: 604–612, 2009 19414839
Dao A, Cuffy M, Kaiser TE, Loethen A, Cafardi J, Luckett K, Rike AH, Cardi M, Alloway RR, Govil A, Diwan T, Sherman KE, Shah SA, Woodle ES: Use of HCV Ab+/NAT- donors in HCV naïve renal transplant recipients to expand the kidney donor pool. Clin Transplant 33: e13598, 2019 31104346
La Hoz RM, Sandıkçı B, Ariyamuthu VK, Tanriover B: Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals. Am J Transplant 19: 3058–3070, 2019 31207073
de Vera ME, Volk ML, Ncube Z, Blais S, Robinson M, Allen N, Evans R, Weissman J, Baron P, Kore A, Bratton C, Garnett G, Hoang T, Wai P, Villicana R: Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremia. Am J Transplant 18: 2451–2456, 2018 30040178
Goldberg DS, Abt PL, Blumberg EA, Van Deerlin VM, Levine M, Reddy KR, Bloom RD, Nazarian SM, Sawinski D, Porrett P, Naji A, Hasz R, Suplee L, Trofe-Clark J, Sicilia A, McCauley M, Farooqi M, Gentile C, Smith J, Reese PP: Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med 376: 2394–2395, 2017 28459186
Durand CM, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N, Wesson R, Reyad A, Naqvi FF, Ostrander D, Sugarman J, Segev DL, Sulkowski M, Desai NM: Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: An open-label nonrandomized trial. Ann Intern Med 168: 533–540, 2018 29507971
Potluri VS, Goldberg DS, Mohan S, Bloom RD, Sawinski D, Abt PL, Blumberg EA, Parikh CR, Sharpe J, Reddy KR, Molnar MZ, Sise M, Reese PP: National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys. J Am Soc Nephrol 30: 1939–1951, 2019 31515244
Molnar MZ, Nair S, Cseprekal O, Yazawa M, Talwar M, Balaraman V, Podila PSB, Mas V, Maluf D, Helmick RA, Campos L, Nezakatgoo N, Eymard C, Horton P, Verma R, Jenkins AH, Handley CR, Snyder HS, Cummings C, Agbim UA, Maliakkal B, Satapathy SK, Eason JD: Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience. Am J Transplant 19: 3046–3057, 2019 31306549
Feld JJ, Cypel M, Kumar D, Dahari H, Pinto Ribeiro RV, Marks N, Kamkar N, Bahinskaya I, Onofrio FQ, Zahoor MA, Cerrochi O, Tinckam K, Kim SJ, Schiff J, Reichman TW, McDonald M, Alba C, Waddell TK, Sapisochin G, Selzner M, Keshavjee S, Janssen HLA, Hansen BE, Singer LG, Humar A: Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: A phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol 5: 649–657, 2020 32389183
Kapila N, Menon KVN, Al-Khalloufi K, Vanatta JM, Murgas C, Reino D, Ebaid S, Shaw JJ, Agrawal N, Rhazouani S, Navas V, Sheffield C, Rahman AU, Castillo M, Lindenmeyer CC, Miller C, Quintini C, Zervos XB: Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus-negative recipients: A real-world experience. Hepatology 72: 32–41, 2020 31659775
Woolley AE, Singh SK, Goldberg HJ, Mallidi HR, Givertz MM, Mehra MR, Coppolino A, Kusztos AE, Johnson ME, Chen K, Haddad EA, Fanikos J, Harrington DP, Camp PC, Baden LR; DONATE HCV Trial Team: Heart and lung transplants from HCV-infected donors to uninfected recipients. N Engl J Med 380: 1606–1617, 2019 30946553
Gupta G, Zhang Y, Carroll NV, Sterling RK: Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy. Am J Transplant 18: 2496–2505, 2018 30075489
Kadatz M, Klarenbach S, Gill J, Gill JS: Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients. Am J Transplant 18: 2457–2464, 2018 29797402
Axelrod DA, Lentine KL, Balakrishnan R, Chang S-H, Alhamad T, Xiao H, Kasiske BL, Bloom RD, Schnitzler MA: Financial evaluation of kidney transplant with hepatitis C viremic donors to uninfected recipients. Transplant Direct 6: e627, 2020 10.1097/TXD.0000000000001056
doi: 10.1097/TXD.0000000000001056
Gupta G, Yakubu I, Bhati CS, Zhang Y, Kang L, Patterson JA, Andrews-Joseph A, Alam A, Ferreira-Gonzalez A, Kumar D, Moinuddin IK, Kamal L, King AL, Levy M, Sharma A, Cotterell A, Reichman TW, Khan A, Kimball P, Stiltner R, Baldecchi M, Brigle N, Gehr T, Sterling RK: Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients. Am J Transplant 20: 739–751, 2020 31652392
Kling CE, Perkins JD, Landis CS, Limaye AP, Sibulesky L: Utilization of organs from donors according to hepatitis C antibody and nucleic acid testing status: Time for change. Am J Transplant 17: 2863–2868, 2017 10.1111/ajt.14386
doi: 10.1111/ajt.14386
Bowring MG, Holscher CM, Zhou S, Massie AB, Garonzik-Wang J, Kucirka LM, Gentry SE, Segev DL: Turn down for what? Patient outcomes associated with declining increased infectious risk kidneys. Am J Transplant 18: 617–624, 2018 29116674
Bowring MG, Shaffer AA, Massie AB, Cameron A, Desai N, Sulkowski M, Garonzik-Wang J, Segev DL: Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States. Am J Transplant 19: 2329–2341, 2019 30861279
Organ Procurement and Transplantation Network: A Guide to Calculating and Interpreting the Kidney Donor Profile Index (KDPI), 2020. Available at: https://optn.transplant.hrsa.gov/media/1512/guide_to_calculating_interpreting_kdpi.pdf . Accessed June 1, 2020